ALDAGEN
is a biopharmaceutical company developing proprietary regenerative cell
therapies that target significant unmet medical needs. We have four
product candidates in clinical trials. Our most advanced product
candidate is ALD-101. We are currently conducting a pivotal Phase 3
clinical trial of ALD-101 to evaluate its efficacy in improving
umbilical cord blood, or cord blood, transplants used to treat
inherited metabolic diseases in pediatric patients. We are also
conducting or supporting Phase 1 or Phase 1/2 clinical trials of three
other product candidates ALD--151 to improve cord blood transplants
used for the treatment of leukemia; ALD-301 to treat critical limb
ischemia; and ALD-201 to treat ischemic heart failure.
04.06.09 - Download PDF
Stem cell therapy grows new blood vessels
11.20.08 - Download PDF
Aldagen announces positive results for ALD-301
10.30.08 - Download PDF
Aldagen Receives Orphan Drug Designation for ALD-101
